The eicosanoids consist of the prostaglandins (PG), thromboxanes (TX), leukotrienes (LT) and lipoxins (LX). The PGs and TXs are collectively identified as prostanoids. The nomenclature of the prostanoids includes a subscript number which refers to the number of carbon-carbon double bonds that exist in the molecule. The majority of the biologically active prostaglandins and thromboxanes are referred to as series 2 molecules due to the presence of two carbon-carbon double bonds. The predominant leukotrienes are series 4 molecules due to the presence of four carbon-carbon double bonds. There are, however, important series 1 prostaglandins and thromboxanes as described below.
Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes) and leukotrienes from leukocytes, hence the derivation of their names. The lipoxins are inflammation resolving eicosanoids synthesized through lipoxygenase interactions (hence the derivation of the name). Lipoxins are potent inflammation modulating eicosanoid derivatives and their synthesis can be increased in response to ingestion of aspirin (see the Lipid-Derived Inflammatory Modulators page for more details on lipoxin functions). Additional inflammation modulating lipid compounds, whose synthesis can also be triggered by aspirin, are the resolvins (Rv) and the protectins (PD) and these are also discussed in the Lipid-Derived Inflammatory Modulators page.
The eicosanoids produce a wide range of biological effects on inflammatory responses (predominantly those of the joints, skin and eyes), on the intensity and duration of pain and fever, and on reproductive function (including the induction of labor). They also play important roles in inhibiting gastric acid secretion, regulating blood pressure through vasodilation or constriction, and inhibiting or activating platelet aggregation and thrombosis.
The principal eicosanoids of biological significance to humans are a group of molecules derived from the C20 fatty acid, arachidonic acid. Additional biologically significant eicosanoids are derived from dihomo-γ-linolenic acid (DGLA) which is produced in the reaction pathway leading to arachidonic acid from linoleic acid (see Figure below). Minor eicosanoids are derived from eicosapentaenoic acid which is itself derived from α-linolenic acid or obtained in the diet. The major source of arachidonic acid is through its release from cellular stores. Within the cell, it resides predominantly at the C–2 position of membrane phospholipids and is released from there upon the activation of PLA2 (see Lipid Synthesis page for details).
The immediate dietary precursor of arachidonic acid is the 18-carbon essential fatty acid, linoleic acid. Linoleic acid is converted to arachidonic acid through the steps outlined in the Figure below. The activity of the Δ6-desaturase (D6D) is slow and can be further compromised due to nutritional deficiencies as well as during inflammatory conditions. Therefore, maximal capacity for synthesis of arachidonic acid occurs with ingested γ-linolenic acid (GLA), the product of the Δ6-desaturase reaction. The D6D enzyme is officially called fatty acid desaturase 2 which is encoded by the FADS2 gene located on chromosome 11q12.2 and is composed of 14 exons that generate three alternatively spliced mRNAs. GLA is converted to dihomo-γ-linolenic acid (DGLA) via the microsomal (ER) fatty acid elongation pathway. DGLA is subsequently further unsaturated to arachidonic acid by the enzyme Δ5-desaturase (D5D). The D5D enzyme is officially called fatty acid desaturase 1 which is encoded by the FADS1 gene located on chromosome 11q12.2–q13.1 and is composed of 13 exons that encode a 501 amino acid protein. Like the Δ6-desaturase, the activity of the Δ5-desaturase is limiting in arachidonic acid synthesis and its activity is also influenced by diet and environmental factors. Due to the limited activity of the Δ5-desaturase most of the DGLA formed from GLA is inserted into membrane phospholipids at the same C-2 position as for arachidonic acid.
The major dietary sources of GLA are borage oil, evening primrose seed oil, hemp seed oil, and black currant seed oil. Diets containing sources of GLA have been shown have distinct cardiovascular benefit similar to diets rich in omega-3 polyunsaturated fatty acids such as is found in cold water fishes (see above).
Arachidonic acid synthesis. Synthesis of arachidonic acid, a polyunsaturated fatty acid (PUFA) of 20 carbon atoms with four sites of unsaturation, begins with the CoA-activated form of linoleic acid (linoleoyl-CoA) which is an 18 carbon fatty acid with two sites of unsaturation. The process of arachidonic acid synthesis, therefore, involves both elongation and two separate desaturation steps.
All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signaling pathways.
Two main pathways are involved in the biosynthesis of eicosanoids. The prostaglandins and thromboxanes are synthesized by the cyclic pathway, the leukotrienes by the linear pathway.
The cyclic pathway is initiated through the action of prostaglandin G/H synthase, PGS (also called prostaglandin-endoperoxide synthetase). This enzyme possesses two activities, cyclooxygenase (COX) and peroxidase. There are two forms of the COX activity in humans, COX-1 and COX-2. COX-1 (PGS-1) is expressed constitutively in gastric mucosa, kidney, platelets, and vascular endothelial cells. COX-2 (PGS-2) is inducible and is expressed in macrophages and monocytes in response to inflammation. The primary triggers for COX-2 induction in monocytes and macrophages are platelet-activating factor, PAF and interleukin-1, IL-1. Both COX-1 and COX-2 catalyze the 2-step conversion of arachidonic acid to PGG2 and then to PGH2. The gene encoding COX-1 is identified as the PTGS1 gene and that encoding COX-2 is the PTGS2 gene. The PTGS1 gene is located on chromosome 9q3232–q33.3 and is composed of 14 exons that generates 6 alternatively spliced variant mRNAs. The PTGS2 gene is located on chromosome 1q25.2–q25.3 and is composed of 10 exons that encode a protein of 604 amino acids.
Synthesis of the clinically relevant prostaglandins and thromboxanes from arachidonic acid. Numerous stimuli (e.g. epinephrine, thrombin and bradykinin) activate PLA2 which hydrolyzes arachidonic acid from cellular membrane phospholipids. As shown, the bradykinin receptor (specifically BDKR2) is coupled to both Gi/0 and Gq G-protein activation with the net effect that there is increased intracellular calcium and activation of PKC. Both PKC phosphorylation and the Ca2+ ions activate the ER membrane-associated cPLA2 isoforms which, when activated, hydrolyze arachidonic acid from PIP2. Arachidonic acid is converted to PGH2 via the action of the bi-functional enzymes COX-1 and COX-2 (also called prostaglandin G/H synthase, PGS or prostaglandin endoperoxide synthetase). The prostaglandins are identified as PG and the thromboxanes as TX. Prostaglandin PGI2 is also known as prostacyclin. PGE2 is synthesized from PGH2 via the action of one of several PGE synthases, where PGE synthase-1 (PGES1) appears to be the key enzyme. Two forms of PGD2 synthases have been identified that convert PGH2 to PGD2. One is encoded by the HPGDS (hematopoietic prostaglandin D synthase) gene and the other is encoded by the PTGDS (prostaglandin D2 synthase). The enzyme encoded by the HPGDS gene is a member of the large family of cytosolic glutathione S-transferase enzymes. Prostacyclin (PGI2) is synthesized from PGH2 via the action of prostacyclin synthase (PTGIS). Prostaglandin F synthase 1 (PGFS) converts PGH2 to PGF2α and it can also convert PGD2 to 9α,11β-PGF2α,β. The principal thromboxanes (TXA2 and TXB2) are derived from PGH2 via the action if thromboxane synthase. The three most physiologically significant cyclic eicosanoids are enclosed in the red boxes. Green arrows denote positive effects. The subscript 2 in each molecule refers to the number of carbon-carbon double bonds present. LPI: lysophosphatidylinositol. Place mouse over structure names to see the structure.
The linear pathway is initiated through the action of arachidonate lipoxygenases (LOXs) of which there are three forms, 5-LOX, 12-LOX and 15-LOX. The official names for these three enzymes are arachidonate 5-lipoxygenase, arachidonate 12-lipoxygenase, and arachidonate 15-lipoxygenase. The 5-LOX enzyme is encoded by the ALOX5 gene which is located on chromosome 10q11.2 and is composed of 14 exons that generate 3 alternatively spliced mRNAs. The 12-LOX enzyme is encoded by the ALOX12 gene which is located on chromosome 17p13.1 and is composed of 14 exons that encode a protein of 663 amino acids. The 15-LOX enzyme is encoded by the ALOX15 gene which is located on chromosome 17p13.3 and is composed of 14 exons that encode a protein of 662 amino acids. It is 5-LOX that gives rise to the leukotrienes. The leukotrienes are synthesized by several different cell types including white blood cells (leukocytes, hence the derivation of the name of the compounds), mast cells, lung, spleen, brain and heart. The activities of 12-LOX and 15-LOX are involved in the synthesis of the lipoxins.
Synthesis of the clinically relevant leukotrienes from arachidonic acid. The leukotrienes are identified as LT. Numerous stimuli (e.g. epinephrine, thrombin and bradykinin) activate PLA2 which hydrolyzes arachidonic acid from cellular membrane phospholipids. As shown, the bradykinin receptor (specifically BDKR2) is coupled to both Gi/0 and Gq G-protein activation with the net effect that there is increased intracellular calcium and activation of PKC. Both PKC phosphorylation and the Ca2+ ions activate the ER membrane-associated cPLA2 isoforms which, when activated, hydrolyze arachidonic acid from PIP2. The enzyme, 5-lipoxygenase (5-LOX) in association with the protein, 5-LOX activating protein (FLAP), catalyzes the conversion of arachidonic acid, first to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) which spontaneously reduces to 5-hydroxyeicosatetraenoic acid (5-HETE), and then to LTA4. LTA4 is unstable and is converted to LTB4 in neutrophils and monocytes harboring LTA4 hydrolase. LTB4 is enclosed in a red box to denote its critical significance as one of the most potent inflammation-mediating lipids. In mast cells and eosinophils, which harbor LTC4 synthase, LTA4 is converted to LTC4. The leukotrienes LTC4, LTD4, LTE4 and LTF4 are known as the peptidoleukotrienes or the cysteinyl leukotrienes because of the presence of amino acids. The peptidoleukotrienes, LTC4, LTD4 and LTE4 are components of slow-reacting substance of anaphylaxis (SRSA). SRSA was originally identified as an activity released from sensitized lung after immunologic challenge. Green arrows denote positive effects. LPI: lysophosphoinositol. The subscript 4 in each molecule refers to the number of carbon-carbon double bonds present. Place mouse over structure names to see the structure.
The lipoxins are synthesized through the concerted actions of 15-LOX (acting on arachidonic acid in epithelial cells, such as in the airway) followed by 5-LOX in leukocytes or through the actions of 5-LOX in leukocytes followed by 12-LOX action in platelets. Details of the functions of the lipoxins can be found in the Lipid-Derived Inflammatory Modulators page.
Synthesis of the lipoxins from arachidonic acid via transcellular interactions. Three pathways exist for the synthesis of the lipoxins. The "classic" pathway involves 5-LOX activity in leukocytes followed by 12-LOX action in platelets. The action of 15-LOX in epithelial cell (such as in the airway) followed by 5-LOX action in leukocytes is the second major lipoxin synthesis pathway. The action of aspirin on COX-2 (see the Lipid-Derived Inflammatory Modulators page for more details) in epithelial, or endothelial cells as wells as in monocytes results in the eventual production of the 15 epi-lipoxins (also referred to as aspirin triggered lipoxins, ATLs).back to the top
Each of the eicosanoids functions via interactions with cell-surface receptors that are members of the G-protein coupled receptor (GPCR) family. There are at least ten characterized prostaglandin receptors. Receptors that bind the prostaglandin D family of lipids are called the DP receptors, those that bind E family prostaglandins are called the EP receptors, those that bind F family prostaglandins are called the FP receptors, those that bind prostacyclin (PGI2) are called the IP receptors, and those that bind the thromboxanes are called the TP receptors.
Two members of the DP receptor family have been described, DP1 (DP1) and DP2 (DP2). The DP1 receptor is encoded by the PTGDR gene located on chromosome 14q22.1 and is composed of 4 exons that generate two alternately spliced mRNAs. The DP2 receptor is encoded by the PTGDR2 gene located on chromosome 11q12–q13.3 and is composed of 2 exons the encode a protein of 395 amino acids. An earlier designation for the PTGDR2 gene was GPR44 as it was originally characterized as an orphan GPCR. Although the DP2 receptor does indeed bind PGD2 as a natural ligand, it is not related to the functional family (class A: rhodopsin) of the other prostanoid receptors but is a member of the chemoattractant (class B) receptor family. The DP1 receptor is coupled to the activation of a Gs-type G-protein.
There are four members of the EP receptor family, EP1 (EP1), EP2 (EP2), EP3 (EP3), and EP4 (EP4). The EP1 receptor is encoded by the PTGER1 gene located on chromosome 19p13.1 and is composed of 3 exons that encode a protein of 402 amino acids. The EP2 receptor is encoded by the PTGER2 gene located on chromosome 14q22 and is composed of 2 exons that encode a protein of 358 amino acids. The EP3 receptor is encoded by the PTGER3 gene located on chromosome 1p31.2 and is composed of 11 exons that generate at least 8 alternatively spliced mRNAs. The EP4 receptor is encoded by the PTGER4 gene located on chromosome 5p13.1 and is composed of 7 exons that encode a protein of 488 amino acids. The EP2 and EP4 receptors are coupled to the activation of a Gs-type G-protein, the EP1 receptor is coupled to the activation of a Gq-type G-protein, and the EP3 receptor has been shown to activate both Gq- and Gi-type G-proteins.
The receptor for the thromboxanes is called the TP receptors. The TP receptor binds thromboxane A2 (TXA2) and it is encoded by the TBXA2R gene which is located on chromosome 19p13.3 and is composed of 5 exons that generate multiple alternatively spliced mRNAs that encode two characterized protein, one of 343 amino acids (the α isoform) and one of 407 amino acids (the β isoform). The TP receptor is coupled to the activation of a Gq-type G-protein.
The receptor for prostacyclin (PGI2) is called the IP receptor. The IP receptor is encoded by the PTGIR gene which is located on chromosome 19q13.3 and is composed of 6 exons that encode a protein of 386 amino acids. The IP receptor couples to the activation of a Gs-type G-protein.
The PGF2α receptor is identified as the FP receptor. The FP receptor is encoded by the PTGFR gene which is located on chromosome 1p31.1 and is composed of 7 exons that encode two alternatively spliced mRNAs. The FP receptor is coupled to the activation of a Gs-type G-protein.
There are at least four leukotriene receptors. Two receptors have been characterized that bind LTB4 called BLT1 and BLT2 and two receptors that bind the peptidoleukotrienes (cysteinyl leukotrienes) called CysLT1 and CysLT2. The BLT1 receptor is encoded by the LTB4R gene located on chromosome 14q11.2–q12 and is composed of 3 exons that generates two variant mRNAs that both encode a protein of 352 amino acids. The BLT2 receptor is encoded by the LTB4R2 gene which is located on chromosome 14q12 and is composed of 2 exons generate two variant mRNAs that both encode a protein of 358 amino acids. The CysLT1 receptor is encoded by the CYSLTR1 gene located on the X chromosome (Xq13.2–q21.1) and is composed of 5 exons that generates four variant mRNAs, each of which encode the same 337 amino acid protein. The CysLT2 receptor is encoded by the CYSLTR2 gene located on chromosome 13q14.2 and contains a single exon encoding a protein of 346 amino acids.back to the top
As indicated in the Table below, the major actions of the series-2 prostaglandins and thromboxanes (predominantly PGE2 and TXA2) are pro-inflammatory as are the series-4 leukotrienes (predominantly LTB4). Thus, it makes sense that drugs that reduce the production of these compounds would be beneficial at reducing inflammation and the associated vascular pathologies. A widely used class of drugs, the non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, indomethacin, naproxen, and phenylbutazone all act upon the cyclooxygenase activity, inhibiting both COX-1 and COX-2. Aspirin is unique among the class of NSAIDs in that its actions on relief from pain (analgesia) and as an anti-inflammatory as well as a heart protective drug are not solely due to its ability to inhibit COX activity (see the Lipid-Derived Inflammatory Modulators page for details).
Research over the past 10–15 years has demonstrated the physiological benefits (i.e. anti-inflammatory; pro-resolution) of alternative pathways of polyunsaturated fatty acid metabolism. Much of this topic is covered in the Lipid-Derived Inflammatory Modulators page. As described above for the synthesis of arachidonate, much of the DGLA derived from ingested linoleic acid or GLA is diverted into membrane phospholipids due to the inefficiency of the Δ5-desaturase catalyzing the conversion of DGLA to arachidonic acid. Incorporation of DGLA into membrane phospholipids competes with the incorporation of arachidonate so that diets enriched in GLA result in an alteration in the ratio of membrane arachidonate to DGLA. Release of membrane DGLA occurs through the action of PLA2 just as for release of arachidonate. Once DGLA is released it will compete with arachidonate for COXs and LOXs. The products of COX action on DGLA are series-1 prostaglandins (PGE1) and thromboxanes (TXA1). These eicosanoids are structurally similar to the series-2 eicosanoids except, of course, they have a single double bond. Although structurally similar, the series-1 eicosanoids have distinctly different biological actions. PGE1 and TXA1 are anti-inflammatory, they induce vasodilation, and they inhibit platelet aggregation. When DGLA is a substrate for 15-LOX the product is 15-hydroxyeicosatrienoic acid (15-HETrE). 15-HETrE is a potent inhibitor of 5-LOX which is the enzyme responsible for the conversion of arachidonic acid to LTB4. LTB4 is a potent inflammatory molecule through its action on neutrophils, thus, DGLA serves to inhibit inflammation via the linear eicosanoid pathway as well.
Due to the vasodilating action of PGE1 it is used pharmaceutically as alprostadil for the treatment of erectile dysfunction (ED). The ED applications of PGE1 are sold as MUSE® and Caverject®. MUSE is a urethral suppository and Caverject is an injectable version. Alprostadil is also used clinically to treat newborn infants with ductal-dependent congenital heart disease. The administration of alprostadil in these infants maintains a patent ductus arteriosus until surgery can carried out to correct the underlying heart defect. Ductus arteriosus is a normal structure of the fetal heart that allows blood to bypass circulation to the lungs since the fetus does not use his/her lungs in utero. The ductus arteriosus shunts blood flow from the left pulmonary artery to the aorta. Shortly after birth the ductus closes due to the high levels of oxygen the newborn is exposed to at birth. However, in newborns with certain congenital heart defects, maintaining a patent ductus arteriosus is clinically significant.
Because inhibition of COX-1 activity in the gut is associated with NSAID-induced ulcerations, pharmaceutical companies have developed drugs targeted exclusively against the inducible COX-2 activity [e.g. Celebrex® (celecoxib), Prexige® (lumiracoxib) and the recently removed Vioxx® (rofecoxib) and Bextra® (valdecoxib)]. Unlike the effects of aspirin on the action and synthesis activities of COX-2, this latter class of drug does not induce the synthesis of anti-inflammatory lipids. In fact the cardiac benefits of low-dose aspirin are negated when taken along with COX-2 specific inhibitors such as Celebrex.
Another class of anti-inflammatory drug, the corticosteroidal drugs, act to inhibit PLA2, thereby inhibiting the release of arachidonate from membrane phospholipids and the subsequent synthesis of eicosanoids.
|Eicosanoid||Major site(s) of synthesis||Major biological activities|
|LXA4||platelets, endothelial cells, mucosal epithelial cells and other leukocytes via inteactions with PMNs||reduce PMN and eosinophil infiltration to sites of inflammation, stimulate nonphlogistic (non-inflammatory-inducing) monocyte recruitment, stimulate macrophage phagocytosis of apoptotic PMNs, block IL-8 (chemokine) expression, block TNF-α release and actions, stimulate TGF-β action|
|LXB4||platelets, endothelial cells, mucosal epithelial cells and other leukocytes via inteactions with PMNs||same as for LXA4|
|PGD2||mast cells, eosinophils, brain||induces inflammatory responses principally by recruiting eosinophils and basophils; induces bronchoconstriction; involved in androgenetic alopecia, inhibitors of PGD2 being studied to treat male pattern baldness|
|PGE1||induces vasodilation and inhibits platelet aggregation|
|PGE2||kidney, spleen, heart||increases vasodilation and cAMP production, enhancement of the effects of bradykinin and histamine, induction of uterine contractions and of platelet aggregation, maintaining the open passageway of the fetal ductus arteriosus; decreases T-cell proliferation and lymphocyte migration and secretion of IL-1α and IL-2|
|PGF2α||kidney, spleen, heart||increases vasoconstriction, bronchoconstriction and smooth muscle contraction|
|PGH2||precursor to thromboxanes A2 and B2, induction of platelet aggregation and vasoconstriction|
|PGI2||heart, vascular endothelial cells||inhibits platelet and leukocyte aggregation, decreases T-cell proliferation and lymphocyte migration and secretion of IL-1α and IL-2; induces vasodilation and production of cAMP|
|TXA1||induces vasodilation and inhibits platelet aggregation|
|TXA2||platelets||induces platelet aggregation, vasoconstriction, lymphocyte proliferation and bronchoconstriction|
|LTB4||monocytes, basophils, neutrophils, eosinophils, mast cells, epithelial cells||powerful inducer of leukocyte chemotaxis and aggregation, vascular permeability, T-cell proliferation and secretion of INF-γ, IL-1 and IL-2|
|LTC4||monocytes and alveolar macrophages, basophils, eosinophils, mast cells, epithelial cells||component of SRS-A, microvascular vasoconstrictor, vascular permeability and bronchoconstriction and secretion of INF-γ, recruitment of leukocytes to sites of inflammation, enhance mucus secretions in gut and airway|
|LTD4||monocytes and alveolar macrophages, eosinophils, mast cells, epithelial cells||same as LTC4|
|LTE4||mast cells and basophils||same as LTC4|